Social Media Posts Promoted Alzheimer’s Blood Tests
New research shows posts are marketing Alzheimer’s biomarker tests to asymptomatic people, often for a significant cost.
Updated on Sept. 20, 2026 in Alzheimer’s
Live Poll
Do you trust health information found on social media for personal medical screening decisions?
A study published in the Journal of the American Geriatrics Society found that social media accounts frequently promote Alzheimer’s blood tests to asymptomatic individuals. These posts, which reached a combined audience of 114 million followers, raise concerns about the marketing of diagnostic tests to those who may not need them.
Why it matters
The marketing of these tests to people without symptoms can lead to diagnostic confusion and unnecessary testing. Understanding how these services are promoted helps you identify when a medical recommendation online may be driven by financial interests rather than patient care.
A University of Sydney analysis of 188 social media posts across Facebook, Instagram, and TikTok found that over one-third promoted biomarker testing for asymptomatic individuals. While these tests track p-tau217 and p-tau181 markers, the promotion was significantly higher in accounts with financial conflicts.
The players
University of Sydney
A research institution that conducted the analysis of social media content regarding Alzheimer's diagnostics.
Journal of the American Geriatrics Society
A peer-reviewed medical publication that focuses on the health and care of older adults.
The details
Blood-based biomarker tests identify biological brain changes associated with Alzheimer’s by measuring proteins like p-tau217 and p-tau181. While these are legitimate diagnostic tools, the study indicates that online providers may be using them to target healthy individuals. Testing costs vary, ranging from $400 through doctors in Australia to $365 or $600 via online providers.
Timeline
September 20, 2026: Study published in the Journal of the American Geriatrics Society.
Health Landscape
This study highlights the gap between current clinical standards for Alzheimer’s diagnosis and the rapid, unregulated growth of direct-to-consumer marketing. It emphasizes a shift where new blood-based biomarkers are being promoted online, often bypassing the established diagnostic pathways.
Be cautious of medical services promoted on social media that suggest diagnostic testing for healthy individuals without specific symptoms. It is essential to discuss the necessity of any Alzheimer’s blood-based biomarker test with your doctor before pursuing out-of-pocket screening.
The takeaway
Diagnostic testing should be a decision guided by a physician who can assess your specific risk factors and symptoms. Be wary of online advertisements for health screenings that imply a need for testing without prior consultation with your healthcare provider.
Further reading
For more information on the current clinical standards for diagnostic screening, see the latest resources on Alzheimer’s.
Live Poll
Do you trust health information found on social media for personal medical screening decisions?
